Figure 1.
![Figure 1. General approach to treating the bleeding patient. A, apixaban; E, edoxaban; fVIIa, [recombinant] factor VIIa; R, rivaroxaban.](https://ash.silverchair-cdn.com/ash/content_public/journal/hematology/2016/1/10.1182_asheducation-2016.1.612/6/hem088393f1.jpeg?Expires=1723418228&Signature=dkvF9e7S4DD-Xos4hYKqkNZsWZfK~0S27V5cbvs2WPVqzP3Lzj6ywO-rzpfpedJLefCi-ksltBjX0TyeWKvpEH39ity1Sk-W3N82mqRPwMKsaBvbW6ZYd6HgP7TDUCh2P66RpOm0T9HToAhYIl~x7ci7PJ1g5V4RVJ2z0t-xkOA1rZFyZlHzJpOdS5fzKRkwW5i5vovYeXz~uU24qUonc849JPYpnvokCgwx3~4rvL-k4WzKyVJUvjyvpEOuG6WFUTVJ5Mncw3vfdG5enI3N9v8Wo-jrnCDiqGbJwWWA5jHAaA7kh2PfGJINM3kGiLILUz-Ms0EValYEQJaifMLyIw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
General approach to treating the bleeding patient. A, apixaban; E, edoxaban; fVIIa, [recombinant] factor VIIa; R, rivaroxaban.
General approach to treating the bleeding patient. A, apixaban; E, edoxaban; fVIIa, [recombinant] factor VIIa; R, rivaroxaban.
